Prime Medicine, Inc.
Status: Publicly traded
Direct answer
Prime Medicine, Inc. is publicly traded on NASDAQ under the ticker PRME.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role...
Can you invest in Prime Medicine, Inc.?
Yes. Prime Medicine, Inc. trades publicly on NASDAQ as PRME.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Prime Medicine, Inc.
Detailed equity research is provided by MarketSnap.